Core US Patent Expiration for Canakinumab
Canakinumab, sold as Ilaris by Novartis, has its primary US composition of matter patent (US 7,829,090) expiring on November 22, 2030.[1] This covers the key monoclonal antibody structure and grants 20 years from the filing date of June 7, 2010.
When Do Other Key Patents Expire?
Additional US patents protect formulations, methods of use, and manufacturing:
- US 8,119,147 (formulation): Expires April 25, 2033.
- US 7,955,605 (IL-1β binding): Expires August 30, 2028.
- Pediatric exclusivity adds 6 months to some, pushing effective dates to early 2029 or mid-2034.[1]
In Europe, the core patent (EP 1542710) expires December 28, 2024, with supplementary protection certificates extending to 2029 in some countries.[2]
Can Generics or Biosimilars Launch Before 2030?
No full generics yet due to biologics complexity—biosimilars require FDA interchangeability approval. Earliest US biosimilar entry likely post-2030, though challenges like Novartis v. Amgen (2023) could shorten this if patents are invalidated.[1][3] Paragraph IV challenges filed since 2020 target multiple patents.
What Delays Market Entry Beyond Patents?
FDA Orange Book lists 12+ patents for Ilaris, plus 7 years orphan exclusivity (ended 2019) and potential new pediatric extensions. Biosimilar developers must navigate litigation; no approved biosimilars as of 2024.[1]
How Does This Compare to Similar Drugs?
| Drug | Primary Patent Expiry | Notes |
|------|-----------------------|-------|
| Canakinumab (Ilaris) | 2030 | Multiple layered patents[1] |
| Adalimumab (Humira) | 2023 | Biosimilars entered post-patent[4] |
| Anakinra (Kineret) | Expired 2017 | Multiple biosimilars now available[1] |
Novartis sales hit $1.4B in 2023; patent cliffs loom by 2030-2033.[2]
[1]: DrugPatentWatch.com - Ilaris Patents
[2]: FDA Orange Book - Ilaris
[3]: USPTO Patent Database
[4]: DrugPatentWatch.com - Humira